Apply for Dificid (Fidaxomicin) Copay Assistance Now.

Dificid copay assistance refers to financial support programs that help patients afford their fidaxomicin prescription by reducing or eliminating out-of-pocket costs. These programs include manufacturer copay cards, independent charitable foundations, and patient assistance programs that work alongside your existing insurance coverage to make this specialty antibiotic more accessible.

Manufacturer copay card programs typically provide the most substantial savings for commercially insured patients, reducing copays significantly per prescription. These programs work by covering the gap between what your insurance pays and your pharmacy cost, up to a maximum annual benefit amount.

At QuickRx Specialty Pharmacy, we coordinate all aspects of Dificid copay assistance on your behalf. Our patient navigators evaluate your insurance coverage, identify all programs you qualify for, complete the necessary applications, and manage your enrollment throughout treatment — at no cost to you.

To begin accessing Dificid copay assistance, contact QuickRx at (917) 830-2525 or complete the form on this page.

Eligibility for Dificid copay assistance varies depending on the specific program type and your insurance coverage. Generally, manufacturer copay card programs are available to patients with commercial or private health insurance who have a valid Dificid prescription. These programs typically exclude patients covered by government-funded insurance such as Medicare, Medicaid, TRICARE, or VA benefits due to federal anti-kickback regulations.

For patients with government insurance, or those who are uninsured or underinsured, alternative assistance options are available through independent charitable foundations and manufacturer patient assistance programs. These programs have their own eligibility criteria, which may include income verification, residency requirements, and documentation of insurance status.

QuickRx Specialty Pharmacy conducts a comprehensive assessment of your specific situation, identifies all programs you may qualify for, and maximizes your potential savings by layering multiple assistance sources when permitted. Even if you have been denied assistance elsewhere, our experienced team may find alternative pathways you have not yet explored.

The best way to determine your eligibility is to contact our patient navigators for a personalized assessment. Call (917) 830-2525 to get started.

No. QuickRx Specialty Pharmacy provides all copay assistance services completely free of charge to patients. Our commitment to patient care means financial barriers should never prevent someone from accessing the specialty medications they need. You will never receive a bill from QuickRx for copay assistance enrollment, application preparation, program management, or any related support services.

Our patient navigators are dedicated solely to helping you access affordable medication. QuickRx operates on the principle that copay assistance is a standard part of specialty pharmacy care — not an additional expense for patients already managing significant healthcare costs.

This no-cost service extends throughout your entire treatment journey, including initial enrollment, renewals, appeals of denied applications, and transitions between programs as your situation changes.

Dificid (fidaxomicin) is a prescription macrolide antibiotic that was FDA-approved on May 31, 2011. It is used to treat Clostridioides difficile infection (CDI), commonly known as C. diff, in adults and pediatric patients 6 months of age and older.

Fidaxomicin works by inhibiting bacterial RNA polymerase, which stops C. difficile bacteria from synthesizing proteins and growing. Unlike many other antibiotics, fidaxomicin has minimal systemic absorption — meaning it works primarily in the gastrointestinal tract where C. diff infections occur, while largely sparing the rest of the gut microbiome.

Dificid is available as:

• 200 mg tablets (brand and generic)
• 40 mg/mL oral suspension (brand Dificid only)

Generic fidaxomicin (200 mg tablets) is available in the United States and may be a lower-cost alternative. Your healthcare provider will determine which formulation is most appropriate for your treatment.

If you have been prescribed Dificid and need help managing the cost, contact QuickRx at (917) 830-2525.

Dificid (fidaxomicin) may be taken with or without food. Both the tablet and oral suspension formulations are available for different patient populations.

Adult Dosing:

• Initial C. diff infection: 200 mg orally twice daily for 10 days. If there is a delayed response to treatment, a longer duration of up to 14 days may be considered.
• Recurrent C. diff infection: 200 mg twice daily for 10 days, OR 200 mg twice daily for 5 days followed by 200 mg once every other day for 20 days.

Tablet Administration:

• Tablets may be swallowed whole or crushed and mixed with 40 mL of water or applesauce, or 60 mL of Ensure
• Administer crushed tablet preparations as soon as possible after mixing
• Tablets may also be administered via nasogastric (NG) tube

Oral Suspension Administration:

• Remove from refrigerator 15 minutes prior to each dose
• Shake vigorously before measuring each dose
• Use the oral dosing syringe provided for accurate measurement

No dosage adjustment is necessary for patients with any degree of kidney impairment. For liver impairment, no adjustment is predicted to be needed given the minimal systemic absorption of fidaxomicin. Always follow your healthcare provider’s specific dosing instructions.

Clostridioides difficile (C. diff) is a bacterium that causes inflammation of the colon, resulting in severe diarrhea and other gastrointestinal complications. C. diff infection is one of the most common healthcare-associated infections in the United States and can range from mild illness to life-threatening colitis.

Who Is Most at Risk:

• Patients who have recently taken antibiotics, which can disrupt the natural balance of gut bacteria
• Older adults, especially those 65 years and older
• Hospitalized or recently hospitalized patients
• Patients with weakened immune systems or serious underlying health conditions

Symptoms of C. diff Infection Include:

• Watery diarrhea occurring 3 or more times per day
• Abdominal cramping and pain
• Fever
• Nausea and loss of appetite
• Blood or pus in the stool (in more severe cases)

Recurrent C. diff infections are common and increasingly difficult to manage. Prompt and complete treatment with an appropriate antibiotic such as Dificid is essential to reduce the risk of recurrence and serious complications. If you or a loved one has been prescribed Dificid, QuickRx is here to help you access your medication. Call (917) 830-2525.

Like all medications, Dificid (fidaxomicin) can cause side effects. Most side effects are gastrointestinal in nature, which is consistent with its activity in the GI tract.

Most Common Side Effects (occurring in more than 10% of adult patients):

• Nausea (~11%)

Common Side Effects (1% to 10% of patients):

• Abdominal pain (6–8%)
• Vomiting (~7%)
• Gastrointestinal bleeding (adults: ~4%)
• Anemia (adults: ~2%)
• Increased liver enzymes (adults: up to 5%)
• Skin rash or pruritus (<5%)
• Decreased platelet count (adults: <2%)
• Neutropenia (adults: ~2%)

Serious Side Effects — Seek Medical Attention Immediately If You Experience:

• Signs of an allergic reaction: rash, hives, angioedema (swelling of the mouth, face, or throat), difficulty breathing
• Black, tarry, or bloody stools
• Vomiting blood
• Shortness of breath or chest tightness
• Severe or unusual loss of strength or energy
• Chills or high fever

This is not a complete list of side effects. Contact your healthcare provider or QuickRx pharmacist at (917) 830-2525 with any questions or concerns about side effects while taking Dificid.

Dificid does not carry a US Boxed Warning, but several important precautions apply to all patients taking fidaxomicin.

Hypersensitivity Reactions:

Serious hypersensitivity reactions, including angioedema (swelling of the mouth, face, and throat), dyspnea, pruritus, and rash, have been reported with fidaxomicin. If a severe hypersensitivity reaction occurs, Dificid should be discontinued immediately and appropriate medical care initiated.

Macrolide Allergy:

Patients with a known history of macrolide allergy should use Dificid with caution, as they may be at increased risk for hypersensitivity reactions. Discuss your allergy history with your healthcare provider before starting treatment.

Appropriate Use:

Dificid should not be used to treat systemic infections, as its systemic absorption is negligible. It is indicated only for patients with confirmed or strongly suspected C. difficile infections. Use of Dificid in the absence of a proven or suspected C. diff infection increases the risk of developing drug-resistant bacteria.

Sound-Alike Drug Confusion:

Fidaxomicin may be confused with rifaximin, another antibiotic used in GI conditions. Always verify the correct medication name with your pharmacist before dispensing or taking this medication.

Contact your healthcare provider immediately if you experience any of the serious reactions listed above. Our QuickRx pharmacists are also available for clinical questions at (917) 830-2525.

Dificid (fidaxomicin) has some clinically relevant drug interactions. Fidaxomicin is a minor substrate of P-glycoprotein, and while its systemic absorption is minimal, the following interactions are important to be aware of.

Notable Drug Interactions:

• Cholera vaccine: Antibiotics may decrease the therapeutic effect of the cholera vaccine. Avoid the cholera vaccine during antibiotic treatment and for 14 days after completing Dificid.
• Typhoid vaccine (live attenuated, Ty21a strain): Avoid during antibiotic use. Postpone vaccination until at least 3 days after completing Dificid.
• Fecal microbiota (live) products — oral or rectal: Antibiotics may reduce the therapeutic effects of these products. Concurrent use should be avoided.
• Mycophenolate: Antibiotics may decrease active metabolite exposure of mycophenolate. Monitor for changes in immunosuppressive efficacy if used concurrently.
• Mizolastine: Macrolide antibiotics may increase serum concentrations of mizolastine. Concurrent use should be avoided.
• Bacillus clausii: Antibiotics may decrease the therapeutic effects of Bacillus clausii. Separate administration from antibiotic doses during concurrent therapy.
• Sodium picosulfate: Antibiotics may decrease therapeutic effects of sodium picosulfate. Consider alternative bowel cleansing products prior to colonoscopy in patients receiving antibiotics.

Always inform all of your healthcare providers about every medication, supplement, and herbal product you take. Our QuickRx pharmacists review drug interactions as part of our clinical pharmacy services. Call us at (917) 830-2525 with any questions.

Yes. Dificid (fidaxomicin) is FDA-approved for pediatric patients 6 months of age and older for the treatment of Clostridioides difficile infection. The pharmacokinetics of fidaxomicin in pediatric patients 6 months to under 18 years of age are similar to those in adult patients.

Pediatric Dosing — Fixed Dosing by Weight:

• 4 to less than 7 kg: Oral suspension 80 mg twice daily for 10 days
• 7 to less than 9 kg: Oral suspension 120 mg twice daily for 10 days
• 9 to less than 12.5 kg: Oral suspension 160 mg twice daily for 10 days
• 12.5 kg and above: Oral suspension or tablet 200 mg twice daily for 10 days

Pediatric Dosing — Weight-Directed (Limited Data, Children Under 6 Years):

• Infants ≥6 months and Children <6 years: 16 mg/kg/dose twice daily for 10 days (maximum 200 mg/dose)
• Children ≥6 years and Adolescents: 200 mg twice daily for 10 days

No dosage adjustment is necessary for pediatric patients with mild, moderate, or severe kidney impairment. Pediatric dosing should always be determined by your child’s healthcare provider. If your child has been prescribed Dificid and you need help with costs, call QuickRx at (917) 830-2525.

The limited systemic absorption of fidaxomicin may reduce potential fetal or infant exposure. However, as with all medications during pregnancy and breastfeeding, a careful risk-benefit discussion with your healthcare provider is essential.

Pregnancy:

The minimal systemic absorption of fidaxomicin may limit potential fetal exposure. There is no specific contraindication to use during pregnancy; however, clinical data in pregnant patients are limited. Your healthcare provider will weigh the risks and benefits of treating your C. diff infection during pregnancy.

Breastfeeding:

It is not known whether fidaxomicin is present in human breast milk. Given the minimal systemic absorption of the drug, distribution into breast milk is unlikely to be significant. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.

Always consult your healthcare provider with any questions about using Dificid during pregnancy or while breastfeeding.

One of the advantages of Dificid (fidaxomicin) is that its minimal systemic absorption means no dose adjustments are required for most patients with organ impairment.

Kidney Impairment:

No dosage adjustment is necessary for any degree of kidney dysfunction, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (CRRT). Fidaxomicin is unlikely to be dialyzed due to its minimal systemic absorption and negligible renal excretion.

Liver Impairment:

No dosage adjustments are provided in the manufacturer’s labeling, as the drug has not been studied in hepatic impairment. However, given its minimal systemic absorption and lack of significant hepatic metabolism or elimination, dosage adjustment is likely unnecessary.

If you have kidney or liver disease and have questions about your Dificid prescription, our QuickRx pharmacists are happy to review your regimen. Call (917) 830-2525.

Proper storage of Dificid is important to maintain the medication’s effectiveness throughout your course of treatment.

Tablets:

• Store at room temperature: 20°C to 25°C (68°F to 77°F)
• Excursions permitted between 15°C and 30°C (59°F and 86°F)

Oral Suspension (after reconstitution):

• Refrigerate at 2°C to 8°C (36°F to 46°F)
• Use within 12 days of reconstitution; discard any remaining suspension after 12 days
• Do not open the granule pouch until time of use; store in the original bottle
• Remove from refrigerator 15 minutes before each dose; shake vigorously before use

Reconstituting the Oral Suspension:

• Shake the bottle to ensure granules are not caked before adding water
• Reconstitute granules with 130 mL of purified water
• Hold bottle horizontally and shake vigorously for at least 2 minutes until a homogeneous suspension is formed
• Write the discard date (current date plus 12 days) on the bottle

Keep all Dificid formulations out of reach of children. If you have questions about storage or your medication’s appearance, contact your QuickRx pharmacist at (917) 830-2525.

Because Dificid (fidaxomicin) has minimal systemic absorption, it does not require the same intensive laboratory monitoring as many other specialty medications. However, clinical monitoring during treatment is still important.

Clinical Monitoring During Dificid Treatment:

• Signs and symptoms of hypersensitivity: Monitor for rash, hives, swelling, or difficulty breathing throughout the course of treatment
• Treatment response: Monitor for improvement in diarrhea frequency, abdominal pain, and other C. diff symptoms
• Signs of recurrence: After completing treatment, be alert to the return of diarrhea or other C. diff symptoms, as recurrent infections are common
• Infection prevention: Practice proper hand hygiene (soap and water is preferred over hand sanitizer for C. diff) and follow contact precautions as directed by your healthcare provider

Your healthcare provider will determine the appropriate follow-up schedule based on your individual condition and treatment response. Contact your provider promptly if symptoms worsen or do not improve after beginning Dificid.

Yes. Generic fidaxomicin 200 mg tablets are available in the United States. Generic versions contain the same active ingredient as brand-name Dificid and must meet the same FDA standards for quality, strength, purity, and stability.

Available Fidaxomicin Products:

• Brand Dificid: 200 mg tablets and 40 mg/mL oral suspension (Merck Sharp & Dohme LLC)
• Generic fidaxomicin: 200 mg tablets

The oral suspension formulation (40 mg/mL) is currently only available as brand Dificid and may be particularly important for pediatric patients or adults who cannot swallow tablets.

Your healthcare provider and QuickRx pharmacist can help determine whether brand Dificid or generic fidaxomicin is most appropriate for your treatment. QuickRx can assist with copay assistance for both brand and generic versions. Call (917) 830-2525.

QuickRx Specialty Pharmacy is a nationwide specialty pharmacy licensed in all 50 states with deep expertise in specialty infectious disease medications like Dificid. Our dedicated pharmacists and patient navigators understand the urgency of managing a C. diff infection and provide comprehensive support to ensure you can access and afford your medication as quickly as possible.

Our copay assistance expertise sets us apart. We maintain current knowledge of all available Dificid assistance programs, eligibility requirements, and application processes. Our patient navigators handle the time-consuming work of identifying programs, preparing applications, and managing enrollments at no cost — so you can focus on your recovery.

Beyond copay assistance, QuickRx provides clinical pharmacy services tailored to patients on specialty medications. Our pharmacists review your medications for potential interactions, provide counseling on administration and side effect management, and coordinate with your specialist team to optimize your care. We offer convenient home delivery, refill reminders, and proactive monitoring support throughout your treatment.

We accept most insurance plans and work directly with your insurance company to obtain necessary prior authorizations. Contact us today at (917) 830-2525 to start the process.